Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents

Current treatments for renal failure due to multiple myeloma

(2013) Efstathios Kastritis et al.   EXPERT OPINION ON PHARMACOTHERAPY

Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era

(2012) Meletios A. Dimopoulos et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma

(2012) M A Dimopoulos et al.   LEUKEMIA

Light Chain–Induced Acute Renal Failure Can Be Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple Myeloma: Results of a Phase II Study

(2010) Heinz Ludwig et al.   JOURNAL OF CLINICAL ONCOLOGY

Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group

(2010) Meletios A. Dimopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents

(2010) Maria Roussou et al.   LEUKEMIA RESEARCH

Patterns of Multiple Myeloma During the Past 5 Decades: Stable Incidence Rates for All Age Groups in the Population but Rapidly Changing Age Distribution in the Clinic

(2010) Ingemar Turesson et al.   MAYO CLINIC PROCEEDINGS

Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)

(2009) E Kastritis et al.   LEUKEMIA